Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icanticure in Bradykinin Induced Angioedema
NCT07290855Phase 4Completed
- Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of icatibant in Angioedema (bradykinin-mediated) (AE-BK), hereditary angioedema (HAE), sponsored by Nang Kuang Pharmaceutical Co., Ltd.. Started Sep 2024; status: completed.
02
Drugs
icatibant
03
Conditions
Angioedema (bradykinin-mediated) (AE-BK)hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT07290855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290855.